Optimal Treatments for NSCLC Patients Harboring Primary or Acquired <i>MET</i> Amplification
Dantong Sun(Soochow University), Helei Hou(Qingdao University), Wei‐Hua Yan(Qingdao University), Hong Li(University of British Columbia Hospital), Junyan Tao(Qingdao University), Hai Zhou(Yuncheng University), Jingjuan Zhu(Qingdao University), Chaofan Xue(Chinese Academy of Sciences), Yingying Sheng(Qingdao University)
Cited by 13
Related Papers
Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial (TARGET-C)
|The American Journal of Gastroenterology|2020|78
miR‐152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines
|The Prostate|2013|76
miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells
|Molecular and Cellular Biochemistry|2013|69
A new dicoumarin and anticoagulant activity from Viola yedoensis Makino
|Fitoterapia|2009|68
miR-154 inhibits prostate cancer cell proliferation by targeting CCND2
|Urologic Oncology Seminars and Original Investigations|2013|62